Gilead price target raised to $165 from $150 at Wells Fargo

Wells Fargo analyst Mohit Bansal raised the firm’s price target on Gilead (GILD) to $165 from $150 and keeps an Overweight rating on the shares. The firm says HIV growth appears durable and resilient despite policy headwinds, and Wells sees potential for upside in Yeztugo guidance. Upcoming catalysts and new launches offer increasing visibility into additional growth, including from non-HIV portfolio, the firm adds.